Autoimmune Diseases  >>  Byetta (exenatide)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Byetta (exenatide) / AstraZeneca
NCT00923715: Exenatide (Byetta) Versus Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia

Enrolling by invitation
3
63
US
Insulin, Insulin and Exenatide, Insulin and Pramlintide
Baylor College of Medicine, Albert Einstein College of Medicine of Yeshiva University
Diabetes Mellitus, Type 1
12/11
05/12
NCT02735031 / 2016-000790-21: Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes

Completed
2/3
10
Europe
Exenatide, Byetta, Placebo
Radboud University Medical Center, AstraZeneca
Diabetes Mellitus, Type 1, Hypoglycemia
03/18
04/18

Download Options